ArticleCellular oncology (Dordrecht, Netherlands)2012
Expression of the SEPT9_i4 isoform confers resistance to microtubule-interacting drugs.
Article in Cellular oncology (Dordrecht, Netherlands), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- SEPT9 methylation as a diagnostic and predictive biomarker in the progression of ductal carcinoma in situ to invasive breast cancer.Scientific reports · 2025Article
- SEPT9_i1 and Septin Dynamics in Oncogenesis and Cancer Treatment.Biomolecules · 2024Review
- Cinnamaldehyde Downregulation of Sept9 Inhibits Glioma Progression through Suppressing Hif-1Disease markers · 2022Article
- Proteomic profiling of the oncogenic septin 9 reveals isoform-specific interactions in breast cancer cells.Proteomics · 2021Article
- Septin filament coalignment with microtubules depends on SEPT9_i1 and tubulin polyglutamylation, and is an early feature of acquired cell resistance to paclitaxel.Cell death & disease · 2019Article
- Gene isoforms as expression-based biomarkers predictive of drug response in vitro.Nature communications · 2017Article
- A Computational Methodology to Overcome the Challenges Associated With the Search for Specific Enzyme Targets to Develop Drugs AgainstBioinformatics and biology insights · 2017Article
- Septin Mutations in Human Cancers.Frontiers in cell and developmental biology · 2016Review
- Cancer-Related Functions and Subcellular Localizations of Septins.Frontiers in cell and developmental biology · 2016Review
- Septin cooperation with tubulin polyglutamylation contributes to cancer cell adaptation to taxanes.Oncotarget · 2015Article
- Article
- High throughput screening of natural products for anti-mitotic effects in MDA-MB-231 human breast carcinoma cells.Phytotherapy research : PTR · 2014Article
- Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress.Nucleic acids research · 2014Article
- Septin functions in organ system physiology and pathology.Biological chemistry · 2014Review
- Proteomic profile of pre - B2 lymphoblasts from children with acute lymphoblastic leukemia (ALL) in relation with the translocation (12; 21).Clinical proteomics · 2014Article
- Novel septin 9 repeat motifs altered in neuralgic amyotrophy bind and bundle microtubules.The Journal of cell biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe evolutionarily conserved septin family of genes encode GTP binding proteins involved in a variety of cellular functions including cytokinesis, apoptosis, membrane dynamics and vesicle trafficking. Septin proteins can form hetero-oligomeric complexes and interact with other proteins including actin and tubulin. The human SEPT9 gene on chromosome 17q25.3 has a complex genomic architecture with 18 different transcripts that can encode 15 distinct polypeptides. Two distinct transcripts with unique 5' ends (SEPT9_v4 and SEPT9_v4*) encode the same protein. In tumours the ratio of these transcripts changes with elevated levels of SEPT9_v4* mRNA, a transcript that is translated with enhanced efficiency leading to increased SEPT9_i4 protein.
methodsWe have examined the effect of over-expression of SEPT9_i4 on the dynamics of microtubule polymer mass in cultured cells.
resultsWe show that the microtubule network in SEPT9_i4 over-expressing cells resists disruption by paclitaxel or cold incubation but also repolymerises tubulin more slowly after microtubule depolymerisation. Finally we show that SEPT9_i4 over-expressing cells have enhanced survival in the presence of clinically relevant microtubule acting drugs but not after treatment with DNAinteracting agents.
conclusionsGiven that SEPT9 over-expression is seen in diverse tumours and in particular ovarian and breast cancer, such data indicate that SEPT9_v4 expression may be clinically relevant and contribute to some forms of drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.